Oncologica® provides precision oncology testing to address demand for personalised cancer medicine. This enables cancer patients to be matched to the most appropriate targeted therapies and immunotherapies based on their unique tumour mutation profiles.
Oncologica also provides COVID-19 testing services and viral sequencing to track new SARS COVID-19 variants.
Oncologica® was founded in 2014 with a mission to harness molecular sequencing technologies to deliver an increased range of personalised medicine opportunities to patients with cancer.
Oncologica® was one of the first clinically approved laboratories in Europe to harness the power of genomic profiling to deliver personalised cancer medicine. This enables the most comprehensive linkage of specific cancer genetic mutations to the most appropriate targeted therapy.
Oncologica® is at the forefront of providing precision oncology services that help ensure patients derive maximum benefit from a new generation of personalised drugs.
Oncologica® also functions as a Contract Research Organisation (CRO) to support biomarker and drug development programmes. Our proven portfolio of comprehensive genomic profiling and tumour based assays are used to support theranostic programmes at all stages of the cancer development, from discovery through preclinical development to clinical trials.
Oncologica® runs its own in-house R&D programmes focusing on the development of novel diagnostic and therapeutic intervention strategies to improve the clinical management of patients with advanced cancer. Our major focus is to harness the exciting new scientific and technical developments in cancer genomics to improve personalized treatment decisions and patient outcomes.